ATE440096T1 - Substituierte thiazolderivate mit 3- pyridylgruppen, verfahren zu deren herstellung und deren verwendung - Google Patents

Substituierte thiazolderivate mit 3- pyridylgruppen, verfahren zu deren herstellung und deren verwendung

Info

Publication number
ATE440096T1
ATE440096T1 AT01999258T AT01999258T ATE440096T1 AT E440096 T1 ATE440096 T1 AT E440096T1 AT 01999258 T AT01999258 T AT 01999258T AT 01999258 T AT01999258 T AT 01999258T AT E440096 T1 ATE440096 T1 AT E440096T1
Authority
AT
Austria
Prior art keywords
substituents
group optionally
production
hydrocarbon group
pyridyl groups
Prior art date
Application number
AT01999258T
Other languages
English (en)
Inventor
Noritaka Kuroda
Yoshi Nara
Shohei Hashiguchi
Akihiro Tasaka
Masami Kusaka
Masuo Yamaoka
Tomohiro Kaku
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE440096T1 publication Critical patent/ATE440096T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
AT01999258T 2000-12-08 2001-12-07 Substituierte thiazolderivate mit 3- pyridylgruppen, verfahren zu deren herstellung und deren verwendung ATE440096T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000373868 2000-12-08
PCT/JP2001/010723 WO2002046186A1 (fr) 2000-12-08 2001-12-07 Dérivés thiazole substitués porteurs de groupes 3-pyridyl, procédé d'élaboration et leur utilisation

Publications (1)

Publication Number Publication Date
ATE440096T1 true ATE440096T1 (de) 2009-09-15

Family

ID=18843165

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01999258T ATE440096T1 (de) 2000-12-08 2001-12-07 Substituierte thiazolderivate mit 3- pyridylgruppen, verfahren zu deren herstellung und deren verwendung

Country Status (8)

Country Link
US (1) US7067537B2 (de)
EP (1) EP1348706B1 (de)
JP (1) JP2008266349A (de)
AT (1) ATE440096T1 (de)
AU (1) AU2002221080A1 (de)
CA (1) CA2431171A1 (de)
DE (1) DE60139639D1 (de)
WO (1) WO2002046186A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2278003B2 (de) 1999-04-09 2020-08-05 Kyowa Kirin Co., Ltd. Verfahren zur Steuerung der Aktivität von immunologisch funktionellen Molekülen
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7157473B2 (en) * 2002-08-23 2007-01-02 Rigel Pharmaceuticals, Inc. Pyridyl substituted heterocycles useful for treating or preventing HCV infection
US7071223B1 (en) * 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
EP1620412A2 (de) 2003-05-02 2006-02-01 Rigel Pharmaceuticals, Inc. Heterocyclische verbindungen und deren hydroisomere
ES2396565T3 (es) * 2003-05-12 2013-02-22 Pah Usa 15 Llc Inhibidores benzamida del receptor P2X7
WO2005049065A2 (en) * 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
DE602004014189D1 (de) * 2003-12-19 2008-07-10 Rigel Pharmaceuticals Inc Zusammensetzungen und verfahren zur behandlung von hepatitis-c-virus (hcv) infektion
US7514434B2 (en) 2004-02-23 2009-04-07 Rigel Pharmaceuticals, Inc. Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
CA2572119A1 (en) * 2004-06-29 2006-01-12 Warner-Lambert Company Llc Combination therapies utilizing benzamide inhibitors of the p2x7 receptor
AU2005258911A1 (en) * 2004-06-29 2006-01-12 Pfizer Products Inc. Method for preparing 5-`4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3H`1,2,4!triazin-2-YL!-benzamide derivatives by deprotecting the hydroxyl-protected precursers
WO2007027230A2 (en) 2005-05-02 2007-03-08 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
EP2120580B1 (de) * 2007-02-02 2017-12-27 Baylor College Of Medicine Zusammensetzungen und verfahren zur behandlung von stoffwechselerkrankungen
US9233941B2 (en) 2007-02-02 2016-01-12 Baylor College Of Medicine Methods and compositions for the treatment of body weight related disorders
US9085566B2 (en) 2007-02-02 2015-07-21 Baylor College Of Medicine Compositions and methods for the treatment of metabolic and related disorders
US9212179B2 (en) 2007-02-02 2015-12-15 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
TWI469971B (zh) 2007-10-26 2015-01-21 Univ California 二芳基乙內醯脲類化合物
KR20100135255A (ko) * 2008-03-14 2010-12-24 오츠카 세이야쿠 가부시키가이샤 Ｍｍｐ-2 및/또는 ｍｍｐ-9 저해제
GB0818241D0 (en) * 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
DK2718270T3 (da) 2011-06-10 2022-08-01 Merck Patent Gmbh Sammensætninger og fremgangsmåder til fremstillingen af pyrimidin- og pyridinforbindelser med btk-hæmmende aktivitet
US20130184280A1 (en) * 2011-12-21 2013-07-18 Telik, Inc. Substituted thiazoles as vegfr2 kinase inhibitors
KR20150083864A (ko) * 2012-11-16 2015-07-20 에프. 호프만-라 로슈 아게 2-트리플루오로메틸 이소니코틴산 및 에스터의 제조 공정
JP7260540B2 (ja) * 2017-07-11 2023-04-18 サイティアー セラピューティクス，インコーポレイティド Ｒａｄ５１阻害剤
WO2021173917A1 (en) * 2020-02-28 2021-09-02 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3821384A (en) 1972-10-06 1974-06-28 Uniroyal Inc Pharmaceutical compositions containing a4-aryl-2-(3-pyridyl)thiazole and methods of using same
US4153703A (en) * 1977-06-30 1979-05-08 Uniroyal, Inc. Method of controlling insects and acarids with certain aryl-substituted thiazoles
DE3486009T2 (de) 1983-09-09 1993-04-15 Takeda Chemical Industries Ltd 5-pyridyl-1,3-thiazol-derivate, ihre herstellung und anwendung.
NZ221729A (en) 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
NZ224288A (en) 1987-04-22 1989-12-21 Merrell Dow Pharma 17b-(cyclopropylamino)androst-5-en-3b-ol and related compounds and methods using these for treatment of non-humans
US4966898A (en) 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
EP0573534B1 (de) 1991-03-01 1998-12-23 Electrostatic Technology, Inc. Pulverbeschichtungsverfahren zur herstellung von leiterplatten und ähnlichen
US5457102A (en) 1994-07-07 1995-10-10 Janssen Pharmaceutica, N.V. Pyrroloimidazolyl and imidazopyridinyl substituted 1H-benzimidazole derivatives
ATE186913T1 (de) 1992-03-31 1999-12-15 Btg Int Ltd 17-substituierte steroide, verwendbar bei behandlung von krebs
GB9310635D0 (en) 1993-05-21 1993-07-07 Glaxo Group Ltd Chemical compounds
HUT75871A (en) 1993-09-30 1997-05-28 Yamanouchi Co Azole derivatives and pharmaceutical compositions thereof
WO1996014090A1 (en) 1994-11-07 1996-05-17 Janssen Pharmaceutica N.V. Compositions comprising carbazoles and cyclodextrins
CA2213246A1 (en) * 1995-03-01 1996-09-06 Yamanouchi Pharmaceutical Co., Ltd. Imidazole derivatives and medicinal composition thereof
AU6015796A (en) 1995-06-14 1997-01-15 Yamanouchi Pharmaceutical Co., Ltd. Fused imidazole derivatives and medicinal composition thereof
DK0880540T3 (da) * 1996-02-14 2002-10-07 Aventis Pharma Inc 17-Beta-cyclopropyl(amino/oxy)-4-azasteroider som aktive inhibitorer af testosteron 5-alfa-reduktase og C17-20-lyase
AU2407997A (en) 1996-04-30 1997-11-19 Takeda Chemical Industries Ltd. Combined use of gnrh agonist and antagonist
AU4298997A (en) * 1996-08-26 1998-03-19 Byk Gulden Lomberg Chemische Fabrik Gmbh Thiazole derivatives useful as selective inhibitors of pde-iv
AU4015497A (en) * 1996-08-26 1998-03-19 Byk Gulden Lomberg Chemische Fabrik Gmbh Thiazole derivatives useful as selective inhibitors of pde-iv
JPH10195056A (ja) * 1996-11-12 1998-07-28 Takeda Chem Ind Ltd 縮合ベンゼン誘導体、その製造法および剤
JP2001509166A (ja) * 1997-01-28 2001-07-10 メルク エンド カンパニー インコーポレーテッド 糖尿病および肥満の治療のためのβ▲下３▼作動薬としてのチアゾールベンゼンスルホンアミド
AU6229698A (en) * 1997-02-21 1998-09-09 Takeda Chemical Industries Ltd. Fused ring compounds, process for producing the same and use thereof
JPH1179993A (ja) 1997-09-05 1999-03-23 Sumitomo Pharmaceut Co Ltd 免疫抑制剤
ATE264304T1 (de) 1997-10-02 2004-04-15 Daiichi Seiyaku Co Dihydronaphthalinderivate und verfahren zur herstellung derselben
CA2302417A1 (en) 1997-10-27 1999-05-06 Takeda Chemical Industries, Ltd. Adenosine a3 receptor antagonists
DE69924717T2 (de) 1998-04-23 2006-03-09 Takeda Pharmaceutical Co. Ltd. Naphthalene derivate ,ihre herstellung und verwendung
EA005369B1 (ru) 1999-03-15 2005-02-24 Аксис Фармасьютикалз, Инк. Новые соединения и композиции в качестве ингибиторов протеазы
JP2000302680A (ja) 1999-04-23 2000-10-31 Takeda Chem Ind Ltd 脳保護剤
CA2370264A1 (en) 1999-04-23 2000-11-02 Takeda Chemical Industries, Ltd. 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
WO2001010865A1 (fr) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. INHIBITEURS DE p38MAP KINASE
AU7950100A (en) 1999-10-22 2001-05-08 Takeda Chemical Industries Ltd. 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof
AU2001245764A1 (en) 2000-03-15 2001-09-24 Axys Pharmaceuticals, Inc. Novel compounds and compositions as protease inhibitors
WO2001083461A1 (fr) * 2000-04-28 2001-11-08 Shionogi & Co., Ltd. Derives de thiazole et d'oxazole
AU2002362603A1 (en) * 2001-09-26 2003-04-07 Bayer Corporation 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors

Also Published As

Publication number Publication date
US20040072876A1 (en) 2004-04-15
AU2002221080A1 (en) 2002-06-18
WO2002046186A1 (fr) 2002-06-13
CA2431171A1 (en) 2002-06-13
DE60139639D1 (de) 2009-10-01
EP1348706B1 (de) 2009-08-19
EP1348706A1 (de) 2003-10-01
EP1348706A4 (de) 2005-08-10
US7067537B2 (en) 2006-06-27
JP2008266349A (ja) 2008-11-06

Similar Documents

Publication Publication Date Title
ATE440096T1 (de) Substituierte thiazolderivate mit 3- pyridylgruppen, verfahren zu deren herstellung und deren verwendung
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
DE60309829D1 (de) Glucocorticoid mimetika, verfahren zu ihrer herstellung, pharmazeutische formulierungen sie enthaltend und verwendungen davon
NZ532494A (en) Dibenzylamine compound and medicinal use thereof
BRPI0615111B8 (pt) composto, composição farmacêutica, e, uso do composto
ATE334973T1 (de) Chinazolinverbindungen
ATE403648T1 (de) Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung
CY1109227T1 (el) Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγων
EE200200148A (et) Kinasoliini derivaadid, nende valmistamise meetodning kasutamine
FI924397A (fi) Substituerade pyrimidiner
DE69923300D1 (de) Cycloalken-derivate, verfahren zu ihrer herstellung und ihre verwendung
ATE144772T1 (de) Piperazinderivate
ATE159514T1 (de) Substituierte aminsäure derivate verwendbar für die behandlung von arteriosclerosis
ATE205199T1 (de) Quinolin- oder quinazolinderivate, deren herstellung und verwendung
DE60027034D1 (de) 1-substituierte-phenyl-1-(1h-imidazol-4-yl)alkohole, verfahren zu deren herstellung sowie deren verwendung
DE3867899D1 (de) Verfahren zur herstellung von 4-amino-androstendion-derivaten.
ATE187448T1 (de) Morpholinderivate
ATE214064T1 (de) Indane-1-ol derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
ATE502030T1 (de) Imidazolderivate, verfahren zu deren herstellung und deren verwendung
DK1150974T3 (da) Heterocykliske derivater som inhibitor af faktor Xa
DE69725167D1 (de) N-benzolsulfonyl-l-prolin derivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung
ATE233266T1 (de) 8h-(2,3-b)-pyrrolozin-8-one derivate, verfahren zur ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties